Gelteq Limited Ordinary S... (GELS)
1.05
-0.02 (-1.87%)
At close: Mar 24, 2025, 1:41 PM
Company Description
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals.
It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products.
The company was incorporated in 2017 and is headquartered in Caulfield, Australia.
Gelteq Limited Ordinary Shares
| Country | AU |
| IPO Date | n/a |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Nathan Jacob Givoni |
Contact Details
Address: 641 Glen Huntly Road Caulfield, VIC AU | |
| Website | https://www.gelteq.com |
Stock Details
| Ticker Symbol | GELS |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | AUD |
| CIK Code | 0001920092 |
| CUSIP Number | n/a |
| ISIN Number | n/a |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nathan Jacob Givoni | Co-Founder, Chief Executive Officer & Director |
| Anthony W. Panther A.C.I.S., AGIA, B.E., C.A., L.L.B., LL.B | Chief Financial Officer |
| Adam Bendell | President of U.S. Operations |
| Dr. Paul M. Wynne | Chief Scientific Officer |
| Matthew Jones | Head of Sports Performance |
| Simon Hayden Szewach | Co-Founder & Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2025 | 6-K | Filing |
| Nov 15, 2024 | 20-F | Filing |
| Oct 31, 2024 | NT 20-F | Filing |
| Oct 30, 2024 | 6-K | Filing |
| Oct 28, 2024 | CERT | Filing |
| Oct 22, 2024 | 424B4 | Filing |
| Oct 17, 2024 | 8-A12B | Filing |
| Sep 25, 2024 | F-1/A | [Amend] Filing |
| Sep 12, 2024 | F-1/A | [Amend] Filing |
| Jul 15, 2024 | F-1 | Filing |